Cancer Immunology Bench to Bedside Immunotherapy of Cancers

This translational, clinically oriented book describes in detail novel approaches to cancer immunotherapy, current strategies to target tumor immunosuppression, and prognostic biomarkers for personalized cancer treatments. Since the first, very successful edition of the book was published in 2015, the original chapters have been significantly updated and entirely new chapters are included on, for example, cancer immunoprevention, aptamer-mediated cancer gene therapy, haploidentical bone marrow transplantation for pediatric malignancies, and nanoimmunotherapy.

The book is published as part of the three-volume Springer series Cancer Immunology, which aims to provide an up-to-date, clinically relevant review of cancer immunology and immunotherapy. Other volumes in the series address the translational medicine context and cancer immunotherapy for organ-specific tumors. Cancer Immunology: Bench to Bedside Immunotherapy of Cancers will be of special value to clinical immunologists, hematologists, and oncologists.

 

Frontiers in Cancer Immunotherapy.- Novel Strategy of Cancer Immunotherapy: Spiraling Up.- Novel Prognostic Biomarkers for Personalized Cancer Treatments.- Tumor Antigen and Epitope Identification for Pre-Clinical and Clinical Evaluation.- Strategies to Target Tumor Immunesuppression.- Immune Modulation of Drugs in Prevention and Treatment of Cancers.- Overcoming Immune Tolerance With Immune Checkpoint Blockade.- Gene therapy and Virus-Based Cancer Vaccines.- Cancer Stem Cells: Biology and Potential therapeutic Applications.- Hematopoietic Stem Cell Transplantation and Lymphodepletion in Treatment of Cancers.- Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers.- T Cell Immunotherapy: From Synthetic Biology to Clinical Practice.- Role of Gamma-Delta T Lymphocytes in Cancer Immunosurveillance and Immunotherapy.- Adoptive T Cell therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy.- Cellular therapy of Cancer With B Effector Cells.- Monoclonal Antibodies for Treatment of Cancers.- Pattern Recognition Receptors in Cancers and Immunotherapy by Triggering or Targeting of Toll Like Receptors Pathway.- Recent Advances in the Use of NK Cells Against Cancer.- Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical Trials.- Tumor Associated Macrophages and iNOS in Cancer Immunotherapy.- Photodynamic therapy and Anti-Tumor Immune Response.- Polarization of Tumor Milieu: Therapeutic Implications.- Immunotherapies Targeting 5T4 Oncofoetal Glycoprotein.- Immune Monitoring During Clinical Development of Anti-CTLA-4 Antibody Therapy.- PD-1 Blockade in Cancer Therapy.- New Advances in Radioimmunotherapy for the Treatment of Cancers.- Psychoneuroendocrinoimmunotherapy of Cancers.- Ethical Considerations in Cancer Immunotherapy.

Nima Rezaei gained his medical degree from Tehran University of Medical Sciences in 2002 and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also undertook a short-term fellowship of Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Since 2010, Dr. Rezaei has worked at the Department of Immunology, School of Medicine, Tehran University of Medical Sciences. He is now the Vice Dean of International Affairs, School of Medicine, Tehran University of Medical Sciences; Director of the Global Academic Program, Tehran University of Medical Sciences; and co-founder and Deputy President of the Research Center for Immunodeficiencies. He is also the Founding President of Universal Scientific Education and Research Network (USERN). Dr. Rezaei has already been the director of more than 50 research projects and has designed and participated in several international collaborative projects. He is an editorial assistant or board member for more than 30 international journals. He has edited more than 20 books, has presented more than 450 lectures/posters in congresses/meetings, and has published more than 750 articles in international scientific journals